Literature DB >> 17823811

Kallikrein-kinin activation by altered vitreous pH: New perspectives for treatment and pathogenesis of diabetic macular edema? : Comment on: Gao BB et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007 Feb;13(2):181-8.

O Zeitz1, M Keserü.   

Abstract

Recently, Gao et al. published an experimental study based on the pathophysiology of diabetic macular edema in Nature Medicine (Nat Med. 2007 Feb;13(2):181-8). They found an increased amount of carbonic anhydrase in the vitreous, which causes a pH shift. This activates the kallikrein-kinin system and leads to increased retinal vascular permeability. In this comment the clinical implications of this article are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823811     DOI: 10.1007/s00417-007-0673-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study.

Authors:  S P Shah; M Patel; D Thomas; S Aldington; D A H Laidlaw
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa.

Authors:  Gerald A Fishman; Marsha A Apushkin
Journal:  Br J Ophthalmol       Date:  2007-01-10       Impact factor: 4.638

3.  Long-term effect of acetazolamide in a patient with retinitis pigmentosa.

Authors:  J C Chen; F W Fitzke; A C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-09       Impact factor: 4.799

4.  Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume.

Authors:  T J Wolfensberger; A V Dmitriev; V I Govardovskii
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

5.  The economic burden of major adult visual disorders in the United States.

Authors:  David B Rein; Ping Zhang; Kathleen E Wirth; Paul P Lee; Thomas J Hoerger; Nancy McCall; Ronald Klein; James M Tielsch; Sandeep Vijan; Jinan Saaddine
Journal:  Arch Ophthalmol       Date:  2006-12

6.  Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

Authors:  Christos Haritoglou; Daniel Kook; Aljoscha Neubauer; Armin Wolf; Siegfried Priglinger; Rupert Strauss; Arnd Gandorfer; Michael Ulbig; Anselm Kampik
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

7.  Is acetazolamide effective in the treatment of diabetic macular edema? A pilot study.

Authors:  C Giusti; R Forte; E M Vingolo; P Gargiulo
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

8.  Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage.

Authors:  G Gao; C Shao; S X Zhang; A Dudley; J Fant; J-X Ma
Journal:  Diabetologia       Date:  2003-05-13       Impact factor: 10.122

9.  Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

Authors:  J Fernando Arevalo; Jans Fromow-Guerra; Hugo Quiroz-Mercado; Juan G Sanchez; Lihteh Wu; Mauricio Maia; Maria H Berrocal; Adriana Solis-Vivanco; Michel E Farah
Journal:  Ophthalmology       Date:  2007-04       Impact factor: 12.079

10.  Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema.

Authors:  Donald S Fong; Samara F Strauber; Lloyd Paul Aiello; Roy W Beck; David G Callanan; Ronald P Danis; Matthew D Davis; Stephen S Feman; Frederick Ferris; Scott M Friedman; Charles A Garcia; Adam R Glassman; Dennis P Han; Darma Le; Craig Kollman; Andreas K Lauer; Franco M Recchia; Sharon D Solomon
Journal:  Arch Ophthalmol       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.